Oxford Biomedica PLC (LSE: OXB), the cell and gene therapy contract development and manufacturing organisation (CDMO), has confirmed a manufacturing and supply partnership with Aura Biosciences, Inc. (NASDAQ: AURA) to support late-stage development of Aura's lead oncology candidate, belzupacap sarotalocan (bel-sar). The partnership, established earlier in 2026, covers Phase 3 clinical development activities and preparations for potential future commercial supply of Aura's virus-like drug conjugate (VDC) programme targeting ocular cancers. The announcement signals OXB's strategic expansion into VDC manufacturing, an adjacent segment to its established viral vector expertise, and underlines the commercial utility of its FDA-approved Durham, North Carolina facility.

Key Points

  • Oxford Biomedica PLC (LSE: OXB), a FTSE 250 cell and gene therapy CDMO headquartered in Oxford, UK
  • OXB has confirmed a partnership with Aura Biosciences to support Phase 3 development and future commercial supply of bel-sar, a virus-like drug conjugate targeting ocular cancers
  • Technical transfer has been initiated in preparation for process performance qualification (PPQ) and commercial-scale production at OXB's Durham, North Carolina facility
  • Investors should watch for further updates on PPQ progress, regulatory filings by Aura, and any additional VDC client mandates for OXB

OXB's Durham Facility and Bedford Site Underpin Aura's Bel-Sar Manufacturing Strategy

The partnership draws on two of OXB's US facilities: its process and analytical development site in Bedford, Massachusetts, and its FDA-approved commercial-scale viral vector manufacturing facility in Durham, North Carolina. The Durham site brings drug substance and fill-and-finish capabilities together on a single campus, which the announcement states is central to supporting Aura's manufacturing readiness. OXB has already initiated technical transfer in preparation for PPQ and commercial production, activities designed to underpin both potential future regulatory filings and eventual commercialisation of bel-sar as Aura advances through Phase 3 trials.

Virus-Like Drug Conjugate Programme Marks a New Adjacent Segment for OXB's CDMO Portfolio

OXB's Chief Business Officer, Dr. Sebastien Ribault, is quoted in the announcement describing the partnership as "an exciting opportunity for OXB to step into VDC manufacturing, an adjacent segment that sits close to our core viral vector expertise." The company states this demonstrates its ability to offer a world-class service in VDC manufacturing, complementing its established lentiviral, AAV, adenoviral, MVA, and other viral vector capabilities. OXB notes it brings more than 30 years of viral vector process development, analytical and GMP manufacturing experience to support complex programmes through to commercialisation.

Aura Biosciences' Bel-Sar Targets Ocular Cancers as a Potentially First-in-Class Therapy

Aura Biosciences is described in the announcement as a biotechnology company developing what it characterises as a potentially transformative first-in-class therapy for patients with ocular cancers. Bel-sar is Aura's lead virus-like drug conjugate candidate, and Aura recently disclosed the partnership and its broader manufacturing strategy as part of its Q3 corporate update. The progression of bel-sar through Phase 3 development represents a significant late-stage milestone that investors in both OXB and Aura may be watching closely, given the commercial supply opportunity that successful regulatory outcomes could generate for OXB's Durham facility.

Partnership Reinforces OXB's Late-Stage CDMO Credentials Across Global Cell and Gene Therapy Markets

OXB operates development and manufacturing facilities across Oxfordshire, Lyon, Strasbourg, Bedford, and Durham, serving pharmaceutical and biotechnology clients across multiple viral vector modalities. The Aura partnership adds a VDC programme to OXB's late-stage portfolio, reinforcing its positioning as a CDMO capable of supporting clients from early development through to commercial-scale manufacturing. As a FTSE 250 and FTSE4Good constituent, OXB's ability to secure and publicly confirm partnerships of this nature may be of interest to investors monitoring the company's pipeline of CDMO mandates and facility utilisation at its US sites.